TrialHepatology communications2024

Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis.

Douglas Thorburn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.